The firm will use the funding to begin a pivotal study of its EGFR inhibitor, advance the Phase I study of its CLK inhibitor, and develop its preclinical pan-KRAS program.

The company is eyeing deals less than $2 billion, saying it has enough internal assets to replace losses from generic ...

The biotech plans to use the proceeds to develop its pipeline of in vivo CRISPR-based genetic medicines for cardiometabolic disease, including STX-1150.

Researchers at the Broad Institute, Jackson Laboratory, and Boston Children's Hospital will treat rare disease patients and ...

If approved after priority review, the firm anticipates launching DYNE-251 in the US in the first quarter of next year.

NEW YORK – Biotech Immunome has given the first patient with a solid tumor its fibroblast activation protein (FAP)-targeted radioligand therapy within a clinical trial, the company announced Monday.

The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...

Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...

After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...

NEW YORK – The US Food and Drug Administration has cleared Umoja Biopharma to begin a Phase I/II trial for its CD22-directed in vivo CAR T-cell therapy, UB-VV400, in patients with relapsed or ...

NEW YORK – AstraZeneca has acquired worldwide rights to develop and commercialize Dizal Pharmaceutical's EGFR inhibitor Zegfrovy (sunvozertinib) for up to $1.5 billion, the company announced Tuesday.

The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...